Copyright © 2010 Petar S. Lenert. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. J. P. Messina, G. S. Gilkeson, and D. S. Pisetsky, “Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA,” Journal of Immunology, vol. 147, no. 6, pp. 1759–1764, 1991. View at Scopus
2. A. M. Krieg, A.-K. Yi, S. Matson, et al., “CpG motifs in bacterial DNA trigger direct B-cell activation,” Nature, vol. 374, no. 6522, pp. 546–549, 1995. View at Scopus
3. A. M. Krieg, “CpG motifs in bacterial DNA and their immune effects,” Annual Review of Immunology, vol. 20, pp. 709–760, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
4. T. Tokunaga, H. Yamamoto, S. Shimada, et al., “Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity,” Journal of the National Cancer Institute, vol. 72, no. 4, pp. 955–962, 1984. View at Scopus
5. S. Yamamoto, T. Yamamoto, T. Kataoka, E. Kuramoto, O. Yano, and T. Tokunaga, “Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity,” Journal of Immunology, vol. 148, no. 12, pp. 4072–4076, 1992. View at Scopus
6. H. Hemmi, O. Takeuchi, T. Kawai, et al., “A toll-like receptor recognizes bacterial DNA,” Nature, vol. 408, no. 6813, pp. 740–745, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
7. S. Bauer, C. J. Kirschning, H. Hacker, et al., “Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 16, pp. 9237–9242, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
8. T. Haas, J. Metzger, F. Schmitz, et al., “The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation,” Immunity, vol. 28, no. 3, pp. 315–323, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
9. B. Spies, H. Hochrein, M. Vabulas, et al., “Wagner H: vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice,” Journal of Immunology, vol. 171, no. 11, pp. 5908–5912, 2003. View at Scopus
10. K. Yasuda, P. Yu, C. J. Kirschning, et al., “Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways,” Journal of Immunology, vol. 174, no. 10, pp. 6129–6136, 2005. View at Scopus
11. D. B. Stetson and R. Medzhitov, “Recognition of cytosolic DNA activates an IRF3-dependent innate immune response,” Immunity, vol. 24, no. 1, pp. 93–103, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
12. X. Cortez-Gonzalez, I. Pellicciotta, M. Gerloni, et al., “TLR9-independent activation of B lymphocytes by bacterial DNA,” DNA and Cell Biology, vol. 25, no. 5, pp. 253–261, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
13. H. Wagner and S. Bauer, “All is not Toll: new pathways in DNA recognition,” The Journal of Experimental Medicine, vol. 203, no. 2, pp. 265–268, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
14. A. Takaoka, Z. Wang, M. K. Choi, et al., “DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response,” Nature, vol. 448, no. 7152, pp. 501–505, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
15. T. L. Roberts, A. Idris, J. A. Dunn, et al., “HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA,” Science, vol. 323, no. 5917, pp. 1057–1060, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
16. V. Hornung, S. Rothenfusser, S. Britsch, et al., “Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides,” Journal of Immunology, vol. 168, no. 9, pp. 4531–4537, 2002. View at Scopus
17. K. J. Stacey, M. J. Sweet, and D. A. Hume, “Macrophages ingest and are activated by bacterial DNA,” Journal of Immunology, vol. 157, no. 5, pp. 2116–2122, 1996. View at Scopus
18. K. A. Zarember and P. J. Godowski, “Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines,” Journal of Immunology, vol. 168, no. 2, pp. 554–561, 2002. View at Scopus
19. A.-K. Yi, M. Chang, D. W. Peckham, A. M. Krieg, and R. F. Ashman, “CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry,” Journal of Immunology, vol. 161, pp. 2223–2231, 1998. View at Scopus
20. R. Brummel and P. Lenert, “Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides,” Journal of Immunology, vol. 174, no. 4, pp. 2429–2434, 2005. View at Scopus
21. P. Lenert, R. Brummel, E. H. Field, and R. F. Ashman, “TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production,” Journal of Clinical Immunology, vol. 25, no. 1, pp. 29–40, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
22. T. Sparwasser, E.-S. Koch, R. M. Vabulas, et al., “Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells,” European Journal of Immunology, vol. 28, no. 6, pp. 2045–2054, 1998. View at Publisher · View at Google Scholar · View at Scopus
23. L. Ronnblom and G. V. Alm, “An etiopathogenic role for the type I IFN system in SLE,” Trends in Immunology, vol. 22, no. 8, pp. 427–431, 2001. View at Publisher · View at Google Scholar · View at Scopus
24. M. K. Crow and K. A. Kirou, “Interferon-alpha in systemic lupus erythematosus,” Current Opinion in Rheumatology, vol. 16, no. 5, pp. 541–547, 2004. View at Publisher · View at Google Scholar · View at Scopus
25. H. Vallin, A. Perers, G. V. Alm, and L. Rönnblom, “Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus,” Journal of Immunology, vol. 163, no. 11, pp. 6306–6313, 1999. View at Scopus
26. U. Båve, G. Nordmark, T. Lövgren, et al., “Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism,” Arthritis and Rheumatism, vol. 52, no. 4, pp. 1185–1195, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
27. R. A. Herlands, S. R. Christensen, R. A. Sweet, U. Hershberg, and M. J. Shlomchik, “T cell-independent and Toll-like receptor-dependent antigen-driven activation of autoreactive B cells,” Immunity, vol. 29, no. 2, pp. 249–260, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
28. S. R. Christensen, J. Shupe, K. Nickerson, M. Kashgarian, R. A. Flavell, and M. J. Shlomchik, “Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus,” Immunity, vol. 25, no. 3, pp. 417–428, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
29. X. Wu and S. L. Peng, “Toll-like receptor 9 signaling protects against murine lupus,” Arthritis and Rheumatism, vol. 54, no. 1, pp. 336–342, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
30. H. Hacker, H. Mischak, T. Miethke, et al., “CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation,” EMBO Journal, vol. 17, no. 21, pp. 6230–6240, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
31. P. Ahmad-Nejad, H. Hacker, M. Rutz, S. Bauer, R. M. Vabulas, and H. Wagner, “Bacterial CpG-DNA and lipopolysaccharides activate toll-like receptors at distinct cellular compartments,” European Journal of Immunology, vol. 32, no. 7, pp. 1958–1968, 2002. View at Publisher · View at Google Scholar · View at Scopus
32. D. E. Macfarlane and L. Manzel, “Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds,” Journal of Immunology, vol. 160, no. 3, pp. 1122–1131, 1998. View at Scopus
33. R. Lande, J. Gregorio, V. Facchinetti, et al., “Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide,” Nature, vol. 449, no. 7162, pp. 564–569, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
34. E. Latz, A. Schoenemeyer, A. Visintin, et al., “TLR9 signals after translocating from the ER to CpG DNA in the lysosome,” Nature Immunology, vol. 5, no. 2, pp. 190–198, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. Y.-M. Kim, M. M. Brinkmann, M.-E. Paquet, and H. L. Ploegh, “UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes,” Nature, vol. 452, no. 7184, pp. 234–238, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
36. D. H. Kono, M. K. Haraldsson, B. R. Lawson, et al., “Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 29, pp. 12061–12066, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
37. K. Tabeta, K. Hoebe, E. M. Janssen, et al., “The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9,” Nature Immunology, vol. 7, no. 2, pp. 156–164, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
38. S. E. Ewald, B. L. Lee, L. Lau, et al., “The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor,” Nature, vol. 456, no. 7222, pp. 658–662, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
39. F. E. Sepulveda, S. Maschalidi, R. Colisson, et al., “Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells,” Immunity, vol. 31, no. 5, pp. 737–748, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
40. E. Latz, A. Verma, A. Visintin, et al., “Ligand-induced conformational changes allosterically activate Toll-like receptor 9,” Nature Immunology, vol. 8, no. 7, pp. 772–779, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
41. R. Medzhitov, P. Preston-Hurlburt, E. Kopp, et al., “MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways,” Molecular Cell, vol. 2, no. 2, pp. 253–258, 1998. View at Scopus
42. H. Hacker, R. M. Vabulas, O. Takeuchi, K. Hoshino, S. Akira, and H. Wagner, “Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6,” Journal of Experimental Medicine, vol. 192, no. 4, pp. 595–600, 2000. View at Publisher · View at Google Scholar · View at Scopus
43. M. Muzio, G. Natoli, S. Saccani, M. Levrero, and A. Mantovani, “The human toll signaling pathway: divergence of nuclear factor κb and jnk/sapk activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6),” Journal of Experimental Medicine, vol. 187, no. 12, pp. 2097–2101, 1998. View at Publisher · View at Google Scholar · View at Scopus
44. H. Wagner, “The immunobiology of the TLR9 subfamily,” Trends in Immunology, vol. 25, no. 7, pp. 381–386, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
45. C. Guiducci, C. Ghirelli, M.-A. Marloie-Provost, et al., “PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation,” Journal of Experimental Medicine, vol. 205, no. 2, pp. 315–322, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
46. M. Kerkmann, S. Rothenfusser, V. Hornung, et al., “Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells,” Journal of Immunology, vol. 170, no. 9, pp. 4465–4474, 2003. View at Scopus
47. M. D. Halpern and D. S. Pisetsky, “In vitro inhibition of murine IFNγ production by phosphorothioate deoxyguanosine oligomers,” Immunopharmacology, vol. 29, no. 1, pp. 47–52, 1995. View at Publisher · View at Google Scholar · View at Scopus
48. D. S. Pisetsky and C. F. Reich, “Inhibition of murine macrophage IL-12 production by natural and synthetic DNA,” Clinical Immunology, vol. 96, no. 3, pp. 198–204, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
49. F.-G. Zhu, C. F. Reich, and D. S. Pisetsky, “Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides,” Journal of Leukocyte Biology, vol. 72, no. 6, pp. 1154–1163, 2002. View at Scopus
50. N. Jing, Y. Li, X. Xu, et al., “Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells,” DNA and Cell Biology, vol. 22, no. 11, pp. 685–696, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
51. N. Jing, Y. Li, W. Xiong, W. Sha, L. Jing, and D. J. Tweardy, “G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis,” Cancer Research, vol. 64, no. 18, pp. 6603–6609, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
52. A. M. Krieg, T. Wu, R. Weeratna, et al., “Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 21, pp. 12631–12636, 1998. View at Publisher · View at Google Scholar · View at Scopus
53. Y. Chen, P. Lenert, R. Weeratna, et al., “Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs,” Gene Therapy, vol. 8, no. 13, pp. 1024–1032, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
54. P. Lenert, W. Rasmussen, R. F. Ashman, and Z. K. Ballas, “Structural characterization of the inhibitory DNA motif for the type A[D]-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells,” DNA and Cell Biology, vol. 22, no. 10, pp. 621–631, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
55. R. F. Ashman, J. A. Goeken, J. Drahos, and P. Lenert, “Sequence requirements for oligodeoxyribonucleotide inhibitory activity,” International Immunology, vol. 17, no. 4, pp. 411–420, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
56. P. P. Ho, P. Fontoura, P. J. Ruiz, L. Steinman, and H. Garren, “An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems,” Journal of Immunology, vol. 171, no. 9, pp. 4920–4926, 2003. View at Scopus
57. K. L. Graham, L. Y. Lee, J. P. Higgins, L. Steinman, P. J. Utz, and P. P. Ho, “Treatment with a Toll-like receptor inhibitory GpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice,” Autoimmunity, vol. 43, no. 2, pp. 140–155, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
58. P. Lenert, L. Stunz, A.-K. Yi, A. M. Krieg, and R. F. Ashman, “CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-$\kappa$B activation,” Antisense and Nucleic Acid Drug Development, vol. 11, no. 4, pp. 247–256, 2001. View at Scopus
59. L. L. Stunz, P. Lenert, D. Peckham, et al., “Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells,” European Journal of Immunology, vol. 32, no. 5, pp. 1212–1222, 2002. View at Publisher · View at Google Scholar · View at Scopus
60. P. Lenert, A.-K. Yi, A. M. Krieg, L. L. Stunz, and R. F. Ashman, “Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells,” Oligonucleotides, vol. 13, no. 3, pp. 143–150, 2003. View at Scopus
61. I. Gursel, M. Gursel, H. Yamada, K. J. Ishii, F. Takeshita, and D. M. Klinman, “Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation,” Journal of Immunology, vol. 171, no. 3, pp. 1393–1400, 2003. View at Scopus
62. P. Lenert, K. Yasuda, L. Busconi, et al., “DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fa${\text{s}}^{lpr/lpr}$ mice in vivo,” Arthritis Research and Therapy, vol. 11, no. 3, article R79, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
63. P. Lenert, “Inhibitory oligodeoxynucleotides—therapeutic promise for systemic autoimmune diseases?” Clinical and Experimental Immunology, vol. 140, no. 1, pp. 1–10, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
64. O. Duramad, K. L. Fearon, B. Chang, et al., “Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation,” Journal of Immunology, vol. 174, no. 9, pp. 5193–5200, 2005. View at Scopus
65. R. F. Ashman and P. Lenert, “Structural requirements and applications of inhibitory oligodeoxyribonucleotides,” Immunologic Research, vol. 39, no. 1–3, pp. 4–14, 2007. View at Publisher · View at Google Scholar · View at Scopus
66. T. Haas, J. Metzger, F. Schmitz, et al., “The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation,” Immunity, vol. 28, no. 3, pp. 315–323, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
67. P. S. Patole, D. Zecher, R. D. Pawar, H.-J. Grone, D. Schlondorff, and H.-J. Anders, “G-rich DNA suppresses systemic lupus,” Journal of the American Society of Nephrology, vol. 16, no. 11, pp. 3273–3280, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
68. K. J. Stacey, G. R. Young, F. Clark, et al., “The molecular basis for the lack of immunostimulatory activity of vertebrate DNA,” Journal of Immunology, vol. 170, no. 7, pp. 3614–3620, 2003. View at Scopus
69. M. Rutz, J. Metzger, T. Gellert, et al., “Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner,” European Journal of Immunology, vol. 34, no. 9, pp. 2541–2550, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
70. S. Cornelie, J. Hoebeke, A.-M. Schacht, et al., “Direct evidence that Toll-like Receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition,” Journal of Biological Chemistry, vol. 279, no. 15, pp. 15124–15129, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
71. F. J. Barrat, T. Meeker, J. Gregorio, et al., “Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus,” Journal of Experimental Medicine, vol. 202, no. 8, pp. 1131–1139, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
72. M. Peter, K. Bode, G. B. Lipford, F. Eberle, K. Heeg, and A. H. Dalpke, “Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity,” Immunology, vol. 123, no. 1, pp. 118–128, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
73. A. M. Pearson, A. Rich, and M. Krieger, “Polynucleotide binding to macrophage scavenger receptors depends on the formation of base-quartet-stabilized four-stranded helices,” Journal of Biological Chemistry, vol. 268, no. 5, pp. 3546–3554, 1993. View at Scopus
74. A. Trieu, N. Bokil, J. A. Dunn, et al., “TLR9-independent effects of inhibitory oligonucleotides on macrophage responses to S. typhimurium,” Immunology and Cell Biology, vol. 87, no. 3, pp. 218–225, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
75. P. S. Lenert, “Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus,” Arthritis Research and Therapy, vol. 8, no. 1, article R203, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
76. K. Honda, Y. Ohba, H. Yanai, et al., “Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction,” Nature, vol. 434, no. 7036, pp. 1035–1040, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
77. C. Guiducci, G. Ott, J. H. Chan, et al., “Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation,” Journal of Experimental Medicine, vol. 203, no. 8, pp. 1999–2008, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
78. A. M. Avalos, E. Latz, B. Mousseau, et al., “Differential cytokine production and bystander activation of autoreactive B cells in response to CpG-A and CpG-B oligonucleotides,” Journal of Immunology, vol. 183, no. 8, pp. 6262–6268, 2009.
79. D. Verthelyi, K. J. Ishii, M. Gursel, F. Takeshita, and D. M. Klinman, “Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs,” Journal of Immunology, vol. 166, no. 4, pp. 2372–2377, 2001. View at Scopus
80. A. Krug, S. Rothenfusser, V. Hornung, et al., “Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmocytoid dendritic cells,” European Journal of Immunology, vol. 31, no. 7, pp. 2154–2163, 2001. View at Publisher · View at Google Scholar · View at Scopus
81. M. Kerkmann, L. T. Costa, C. Richter, et al., “Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-$\alpha$ induction by CpG-A in plasmacytoid dendritic cells,” Journal of Biological Chemistry, vol. 280, no. 9, pp. 8086–8093, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
82. N. L. Bernasconi, N. Onai, and A. Lanzavecchia, “A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naïve B cells and constitutive expression in memory B cells,” Blood, vol. 102, no. 11, pp. 956–63, 2003.
83. C. R. Ruprecht and A. Lanzavecchia, “Toll-like receptor stimulation as a third signal required for activation of human naive B cells,” European Journal of Immunology, vol. 36, no. 4, pp. 810–816, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
84. R. Brummel, T. L. Roberts, K. J. Stacey, and P. Lenert, “Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice,” European Journal of Immunology, vol. 36, no. 7, pp. 1951–1962, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
85. H. Poeck, M. Wagner, J. Battiany, et al., “Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help,” Blood, vol. 103, no. 8, pp. 3058–3064, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
86. L. Busconi, J. W. Bauer, J. R. Tumang, et al., “Functional outcome of B cell activation by chromatin immune complex engagement of the B cell receptor and TLR9,” Journal of Immunology, vol. 179, no. 11, pp. 7397–7405, 2007. View at Scopus
87. L. G. Hannum, D. Ni, A. M. Haberman, M. G. Weigert, and M. J. Shlomchik, “A disease-related rheumatoid factor autoantibody is not tolerized in a normal mouse: implications for the origins of autoantibodies in autoimmune disease,” Journal of Experimental Medicine, vol. 184, no. 4, pp. 1269–1278, 1996. View at Publisher · View at Google Scholar · View at Scopus
88. E. A. Leadbetter, I. R. Rifkin, A. M. Hohlbaum, B. C. Beaudette, M. J. Shlomchik, and A. Marshak-Rothstein, “Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors,” Nature, vol. 416, no. 6881, pp. 603–607, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
89. C. M. Lau, C. Broughton, A. S. Tabor, et al., “RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement,” Journal of Experimental Medicine, vol. 202, no. 9, pp. 1171–1177, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
90. S. L. Peng, J. Moslehi, and J. Craft, “Roles of interferon-gamma and interleukin-4 in murine lupus,” Journal of Clinical Investigation, vol. 99, no. 8, pp. 1936–1946, 1997. View at Scopus
91. C. Haas, B. Ryffel, and M. Le Hir, “IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice,” Journal of Immunology, vol. 158, no. 11, pp. 5484–5491, 1997. View at Scopus
92. J. D. Hron and S. L. Peng, “Type I IFN protects against murine lupus,” Journal of Immunology, vol. 173, no. 3, pp. 2134–2142, 2004. View at Scopus
93. M. A. Blasco, S. M. Gasser, and J. Lingner, “Telomeres and telomerase,” Genes and Development, vol. 13, no. 18, pp. 2353–2359, 1999. View at Publisher · View at Google Scholar · View at Scopus
94. D. M. Klinman, D. Tross, S. Klaschik, H. Shirota, and T. Sato, “Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides,” Annals of the New York Academy of Sciences, vol. 1175, pp. 80–88, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
95. H. Shirota, M. Gursel, and D. M. Klinman, “Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma and IL-12-mediated signaling,” Journal of Immunology, vol. 173, no. 8, pp. 5002–5007, 2004. View at Scopus
96. V. Balasubramanian, L. T. Nguyen, S. V. Balasubramanian, and M. Ramanathan, “Interferon-gamma-inhibitory oligodeoxynucleotides alter the conformation of interferon-gamma,” Molecular Pharmacology, vol. 53, no. 5, pp. 926–932, 1998. View at Scopus
97. R. A. Zeuner, D. Verthelyi, M. Gursel, K. J. Ishii, and D. M. Klinman, “Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis,” Arthritis and Rheumatism, vol. 48, no. 6, pp. 1701–1707, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
98. L. Dong, S. Ito, K. J. Ishii, and D. M. Klinman, “Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice,” Arthritis and Rheumatism, vol. 52, no. 2, pp. 651–658, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
99. T. Sato, T. Shimosato, W. G. Alvord, and D. M. Klinman, “Suppressive oligodeoxynucleotides inhibit silica-induced pulmonary inflammation,” Journal of Immunology, vol. 180, no. 11, pp. 7648–7654, 2008. View at Scopus
100. H. Shirota, I. Gursel, M. Gursel, and D. M. Klinman, “Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock,” Journal of Immunology, vol. 174, no. 8, pp. 4579–4583, 2005. View at Scopus
101. L. A. Hanakahi, H. Sun, and N. Maizels, “High affinity interactions of nucleolin with G-G-paired rDNA,” Journal of Biological Chemistry, vol. 274, no. 22, pp. 15908–15912, 1999. View at Publisher · View at Google Scholar · View at Scopus
102. A. Bianchi and T. De Lange, “Ku binds telomeric DNA in vitro,” Journal of Biological Chemistry, vol. 274, no. 30, pp. 21223–21227, 1999. View at Publisher · View at Google Scholar · View at Scopus
103. G. Plitas, B. M. Burt, H. M. Nguyen, Z. M. Bamboat, and R. P. DeMatteo, “Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis,” Journal of Experimental Medicine, vol. 205, no. 6, pp. 1277–1283, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
104. F. J. Barrat, T. Meeker, J. H. Chan, C. Guiducci, and R. L. Coffmann, “Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms,” European Journal of Immunology, vol. 37, no. 12, pp. 3582–3586, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
105. Z.-X. Lian, K. Kikuchi, G.-X. Yang, A. A. Ansari, S. Ikehara, and M. E. Gershwin, “Expansion of bone marrow IFN-alpha-producing dendritic cells in New Zealand Black (NZB) mice: high level expression of TLR9 and secretion of IFN-alpha in NZB bone marrow,” Journal of Immunology, vol. 173, no. 8, pp. 5283–5289, 2004. View at Scopus
106. M.-L. Santiago-Raber, R. Baccala, K. M. Haraldsson, et al., “Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice,” Journal of Experimental Medicine, vol. 197, no. 6, pp. 777–788, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
107. J. Vollmer, S. Tluk, C. Schmitz, et al., “Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8,” Journal of Experimental Medicine, vol. 202, no. 11, pp. 1575–1585, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
108. M. Jurk, A. Kritzler, B. Schulte, et al., “Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides,” European Journal of Immunology, vol. 36, no. 7, pp. 1815–1826, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
109. K. K. B. Gorden, X. Qiu, J. J. L. Battiste, P. P. D. Wightman, J. P. Vasilakos, and S. S. Alkan, “Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines,” Journal of Immunology, vol. 177, no. 11, pp. 8164–8170, 2006. View at Scopus
110. M. Gursel, I. Gursel, H. S. Mostowski, and D. M. Klinman, “CXCL16 influences the nature and specificity of CpG-induced immune activation,” Journal of Immunology, vol. 177, no. 3, pp. 1575–1580, 2006. View at Scopus
111. A. Trieu, T. L. Roberts, J. A. Dunn, M. J. Sweet, and K. J. Stacey, “DNA motifs suppressing TLR9 responses,” Critical Reviews in Immunology, vol. 26, no. 6, pp. 527–544, 2006. View at Scopus
112. B. Park, M. M. Brinkmann, E. Spooner, C. C. Lee, Y.-M. Kim, and H. L. Ploegh, “Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9,” Nature Immunology, vol. 9, no. 12, pp. 1407–1414, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
113. R. D. Pawar, A. Ramanjaneyulu, O. P. Kulkarni, M. Lech, S. Segerer, and H.-J. Anders, “Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus,” Journal of the American Society of Nephrology, vol. 18, no. 6, pp. 1721–1731, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus